Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01548807
Title Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania

prostate adenocarcinoma



Age Groups: adult
Covered Countries USA

No variant requirements are available.